Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
CA: A Cancer Journal for Clinicians · 2026-01 · 76 (1)
DOI: 10.3322/caac.70042 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 25.11.2025. Verfasst von Lingying Wu und 56 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Col…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Pyridines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Hengrui Pharmaceuticals Co., Ltd..
Abstract (Originalsprache)
Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA ‐mutated/homologous recombination‐deficient (HRD) patients, is lacking. This study compared combined fuzuloparib (a PARPi) plus apatinib (a vascular endothelial growth factor receptor‐2 inhibitor) with either fuzuloparib or placebo as first‐line maintenance in patients with advanced OC. Patients who had newly diagnosed, advanced OC and responded to first‐line, platinum‐based chemotherapy were randomized 2:2:1 to receive combined fuzuloparib (100 mg twice daily) plus apatinib (375 mg daily), fuzuloparib (150 mg twice daily) plus placebo, or double‐placebo treatment. The primary end point was blinded independent review committee (BIRC)‐assessed progression‐free survival (PFS). Six hundred seventy‐four patients were randomized to receive fuzuloparib plus apatinib ( n = 269), fuzuloparib ( n = 269), or placebo ( n = 136). At the final analysis (November 1, 2024; 385 BIRC‐assessed PFS events; median follow‐up, 40 months), the median BIRC‐assessed PFS was 26.9 months with the combination versus placebo (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.44–0.75; one‐sided p < .0001) and 29.9 months with fuzuloparib monotherapy versus placebo (HR, 0.58; 95% CI, 0.44–0.75; one‐sided p < .0001) compared with 11.1 months with placebo. A PFS benefit was observed regardless of germline BRCA1/2 mutation status. In homologous recombination‐deficient patients (including those with BRCA1/2 mutations), combined fuzuloparib and apatinib produced a PFS similar to that of fuzuloparib (34.1 vs. 35.8 months, respectively); in homologous recombination‐proficient patients, PFS had a trend favoring the combination (16.6 vs. 11.0 months; HR, 0.73; 95% CI, 0.45–1.19). Both treatments were well tolerated. Overall survival was immature. Both fuzuloparib and combination therapy improved PFS compared with placebo as maintenance therapy for patients who had newly diagnosed, advanced OC. Adding apatinib to fuzuloparib did not prolong PFS among homologous recombination‐deficient patients. There was a PFS benefit trend among homologous recombination‐proficient patients who received combination therapy compared with those who received monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Hunan Cancer Hospital, Changsha, China.
- Affiliated Cancer Hospital of Shandong First Medical University, Jinan, China.
- Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
- Inner Mongolia People's Hospital, Hohhot, China.
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Jianqing Zhu, Ning Li
Förderung
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Zitieren
APA
Wu, L., Wang, J., Li, Q., Wang, D., Zhang, C., Tang, J., Zhang, G., Hao, M., Yao, D., Gao, Q., Zhang, Y., An, R., Yin, R., Wang, L., Xia, B., Zhou, Q., Yang, H., Zhu, J., Jiang, K., …, & Li, N. (2026). Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial. CA: A Cancer Journal for Clinicians, 76(1). https://doi.org/10.3322/caac.70042
Vancouver
Wu L, Wang J, Li Q, Wang D, Zhang C, Tang J, et al. Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial. CA: A Cancer Journal for Clinicians. 2026;76(1). doi:10.3322/caac.70042
BibTeX
@article{Wu2026,
author = {Wu, Lingying and Wang, Jing and Li, Qingshui and Wang, Danbo and Zhang, Cuiying and Tang, Junying and Zhang, Guonan and Hao, Min and Yao, Desheng and Gao, Qinglei and Zhang, Youzhong and An, Ruifang and Yin, Rutie and Wang, Li and Xia, Bairong and Zhou, Qi and Yang, Hongying and Zhu, Jianqing and Jiang, Kui and Chen, Zhengzheng and Wu, Qiang and Duan, Wei and Huang, Yi and Zhang, Hui and Wei, Shuqing and Li, Guiling and Meng, Yuanguang and Wang, Ke and Yang, Xinfeng and Huang, Xianghua and Pan, Lingya and Yu, Jinjin and Lou, Ge and Zhang, Yu and Zhou, Huaijun and Guo, Xiaoqing and Yang, Hong and Cheng, Xiaodong and Li, Xiumin and Wang, Wuliang and Zhao, Hongqin and Li, Yunxia and Yang, Yingjie and Lin, An and Cheng, Wenjun and Chen, Lihong and Xie, Xiaoying and Di, Wen and Hu, Yuanjing and Chen, Mo and Wen, Hongwu and Cai, Liping and Wu, Xiaohua and Lin, Zhongqiu and Wang, Quanren and Yang, Xinfeng and Li, Ning},
title = {Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial},
journal = {CA: A Cancer Journal for Clinicians},
year = {2026},
volume = {76},
number = {1},
doi = {10.3322/caac.70042}
}
EUVIMED